Abbas Engy, Fanni Salvatore Claudio, Bandini Claudio, Francischello Roberto, Febi Maria, Aghakhanyan Gayane, Ambrosini Ilaria, Faggioni Lorenzo, Cioni Dania, Lencioni Riccardo Antonio, Neri Emanuele
The Joint Department of Medical Imaging, University of Toronto, University Health Network, Sinai Health System, Women's College Hospital, 610 University Ave, Toronto, ON, Canada M5G 2M9.
Department of Translational Research, Academic Radiology, University of Pisa, Pisa, Italy.
Eur J Radiol Open. 2023 Jul 18;11:100511. doi: 10.1016/j.ejro.2023.100511. eCollection 2023 Dec.
The new immunotherapies have not only changed the oncological therapeutic approach but have also made it necessary to develop new imaging methods for assessing the response to treatment. Delta radiomics consists of the analysis of radiomic features variation between different medical images, usually before and after therapy.
This review aims to evaluate the role of delta radiomics in the immunotherapy response assessment.
A systematic search was performed in PubMed, Scopus, and Web Of Science using "delta radiomics AND immunotherapy" as search terms. The included articles' methodological quality was measured using the Radiomics Quality Score (RQS) tool.
Thirteen articles were finally included in the systematic review. Overall, the RQS of the included studies ranged from 4 to 17, with a mean RQS total of 11,15 ± 4,18 with a corresponding percentage of 30.98 ± 11.61 %. Eleven articles out of 13 performed imaging at multiple time points. All the included articles performed feature reduction. No study carried out prospective validation, decision curve analysis, or cost-effectiveness analysis.
Delta radiomics has been demonstrated useful in evaluating the response in oncologic patients undergoing immunotherapy. The overall quality was found law, due to the lack of prospective design and external validation. Thus, further efforts are needed to bring delta radiomics a step closer to clinical implementation.
新型免疫疗法不仅改变了肿瘤治疗方法，还使得开发用于评估治疗反应的新成像方法成为必要。差异放射组学包括分析不同医学图像（通常是治疗前后）之间的放射组学特征变化。
本综述旨在评估差异放射组学在免疫治疗反应评估中的作用。
在PubMed、Scopus和Web of Science中进行系统检索，使用“差异放射组学与免疫治疗”作为检索词。使用放射组学质量评分（RQS）工具评估纳入文章的方法学质量。
13篇文章最终纳入系统评价。总体而言，纳入研究的RQS范围为4至17，平均RQS总计为11.15±4.18，相应百分比为30.98±11.61%。13篇文章中有11篇在多个时间点进行成像。所有纳入文章均进行了特征降维。没有研究进行前瞻性验证、决策曲线分析或成本效益分析。
差异放射组学已被证明在评估接受免疫治疗的肿瘤患者的反应中有用。由于缺乏前瞻性设计和外部验证，发现总体质量较低。因此，需要进一步努力使差异放射组学更接近临床应用。
